GlassScriptPhysician profile
Charles I Gold
NPI 1073584330
$6,850.93
in general payments reported to CMS, 2019-2025
18 companies · $1,714 in 2025
The $1,714 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $486 · 2021: $780 · 2022: $1,250 · 2023: $845 · 2024: $744 · 2025: $1,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,285 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,285.07 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,321.99 | 2019-2022 | |
| Abbvie INC. | $888.81 | 2022-2025 | |
| Oyster Point Pharma, INC. | $839.24 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $687.69 | 2020-2025 | Precision7, Simbrinza, Tryptyr |
| Novartis Pharmaceuticals Corporation | $651.15 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $531.16 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Shire North American Group INC | $342.55 | 2019 | |
| Sun Pharmaceutical Industries INC. | $314.24 | 2021-2025 | Cequa |
| Harrow Eye, LLC | $291.36 | 2024-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $215.59 | 2021-2023 | Zerviate, Tobradex St |
| Tarsus Pharmaceuticals, INC. | $182.83 | 2024-2025 | Xdemvy |
| Coopervision INC. | $177.22 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $139.06 | 2025 | Acuvue |
| Kala Pharmaceuticals, INC. | $135.93 | 2021-2022 | |
| Dompe US, INC. | $45.55 | 2024-2025 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.66 | 2020 | |
| Aerie Pharmaceuticals, INC. | $23.76 | 2021 | |
| Thea Pharma INC. | $23.14 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.